Renal
ischemia/reperfusion (I/R) injury is a major cause of
acute kidney injury (AKI), characterized by tubulointerstitial
inflammation. Currently, progress in developing effective
therapies to prevent or ameliorate AKI by anti-
inflammation remains slow. Emerging studies have suggested that NLRP3 (the NOD-, LRR- and pyrin domain-containing 3)
inflammasome plays a key role in a wide spectrum of
kidney disease models including I/R injury. In this study, we investigated the renal protective effects of
A68930, a specific agonist for the D-1
dopamine receptor (DRD1), which was recently recognized to downregulate NLRP3
inflammasome via DRD1 signaling. AKI was induced by renal I/R injury and
A68930 was intraperitoneally injected 3 times after renal reperfusion. We showed that
A68930 significantly ameliorated renal dysfunction. Meanwhile,
A68930 markedly reduced macrophages and T cells infiltration, renal pro-inflammatory
cytokines production (TNF-α, IL-6, IL-1β), serum pro-inflammatory
cytokine (TNF-α and IL-6) and NLRP3
inflammasome activation. Additionally,
A68930 attenuated I/R-induced mitochondria injury, which was observed by transmission electron microscopy. In summary, our results demonstrated that activation of DRD1 by
A68930 inhibited renal and systematic
inflammation, and improved kidney function in I/R induced AKI model, which was probably related to the inhibition of the NLRP3
inflammasome activation.